Salvador Blanch - 10Medica Scientia Innovation Research (MEDSIR), Fundación Instituto Valenciano de Oncología

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 35 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract PS16-02: Efficacy and Safety of First-Line Atezolizumab + Bevacizumab + Paclitaxel in Patients with Advanced Triple-Negative Breast Cancer: the ATRACTIB Phase 2 Trial

Cancer Researchno. 9_Supplement (2024): PS16-02

Cited0Views0Bibtex

Abstract PO1-06-02: Solti-1716 TATEN Phase II Trial: Targeting Non-Luminal Disease by PAM50 with Pembrolizumab and Paclitaxel in Hormone Receptor-positive/HER2-negative Advanced Breast Cancer (ABC)

Aleix Prat,Benedetta Conte,Fara Brasó-Maristany,Nuria Chic,Montserrat Muñoz,Cristina Hernando,Manuel Alva,Silvia Vazquez,Salvador Blanch,Mafalda Oliveira,Esther Fernández,Oleguer Castillo,Patricia Galván, Ángela Aguirre,Esther Sanfeliu,Lorea Villanueva,Tomás Pascual,Eva Ciruelos

Cancer Researchno. 9_Supplement (2024): PO1-06

Cited0Views0Bibtex

Disección Axilar Dirigida Tras Tratamiento Sistémico Primario En Cáncer De Mama N1. Validación De La Técnica Y Experiencia a Los 4 Años

Giovanni Vento, Carlos Fuster, Vincenzo Maisto, Alberto Rios, Joaquin Gavilá,Angel Guerrero,Salvador Blanch, Rosa Ferrer, Josep Asensi, María Elena Mengual, Seyder Morales, Miguel Santos,Maribel Tortajada,José Luis Guinot,Rafael Estevan

Revista de Senología y Patología Mamariano. 3 (2024): 100605

Cited0Views0Bibtex

Abstract PO3-05-06: Targeting PAM50 HER2-Enriched Intrinsic Subtype with Enzalutamide in Hormone Receptor-Positive/her2-negative (HR+/HER2-) Advanced Breast Cancer: Results of the SOLTI-1502 ARIANNA Trial

Mafalda Oliveira,Tomás Pascual,Sonia Pernas,Mireia Margelí,Salvador Blanch,Barbara Adamo,Francisco Javier Salvador Bofill,Xavier Gonzalez-Farré, Samyukta Chillara,Patricia Galván,Esther Sanfeliu,Paula Blasco,Valeria Sirenko,Alejandra Espinosa,Charles M Perou,Aleix Prat,Luis Manso

Cancer Research（2024）

Cited0Views0Bibtex

Prevention of Sacituzumab Govitecan (Sg)-Related Neutropenia and Diarrhea in Patients (pts) with Triple-Negative or HR+/HER2- Advanced Breast Cancer (ABC; PRIMED): A Phase 2 Trial

Jose Manuel Perez Garcia,Maria Gion,Manuel Ruiz-Borrego,Isabel Blancas,Elena Lopez-Miranda,Salvador Blanch,Sabela Recalde,Lourdes Calvo,Xavier Gonzalez, Nerea Ancizar,Serafin Morales Murillo,Patricia Cortez, Javier Cardona,Eileen Shimizu, Jose Antonio Guerrero,Miguel Sampayo-Cordero,Alejandro Martinez-Bueno,Javier Cortes,Antonio Llombart-Cussac

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

Cited0Views0Bibtex

Observational Study of HR+/HER2− Metastatic Breast Cancer Patients Treated with Abemaciclib in Spain in the Named Patient Use Program (Abemuss)

Salvador Blanch,Juan Miguel Gil-Gil,Miriam Arumí,Elena Aguirre,Miguel Ángel Seguí,Manuel Atienza,Silvia Díaz-Cerezo,Alberto Molero,José Manuel Cervera,Joaquín Gavilá

Clinical & translational oncology（2023）

Cited0Views0WOSBibtex

TATEN TRIAL (SOLTI-1716) Targeting Non-Luminal Disease by PAM50 with Pembrolizumab Plus Paclitaxel in Hormone Receptor-positive/HER2-negative (HR+/HER2-) Metastatic Breast Cancer (MBC): Interim Analysis

Aleix Prat,Tomas Pascual,Montserrat Munoz,Cristina Hernando,Silvia Vazquez,Salvador Blanch,Manuel Alva,Mafalda Oliveira,Esther Sanfeliu,Lorea Villanueva,Fara Braso-Maristany,Nuria Chic,Eva Ciruelos

CANCER RESEARCHno. 5 (2023)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn